Novo Nordisk A/S (NVO: Quote) said Friday that the US Food and Drug Administration has approved to update the product label for Victoza to include data showing superior blood sugar control and weight reduction when compared to Januvia.
The update also includes data showing the safety and efficacy of adding basal insulin to Victoza and metformin for the treatment of adults with type 2 diabetes.
The label update is based on data from two large, randomized, open-label studies in adults with type 2 diabetes.
"The data from these studies further demonstrate the strong clinical profile and the value of Victoza in the treatment of type 2 diabetes," said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk.
Click here to receive FREE breaking news email alerts for Novo Nordisk A/S and others in your portfolio
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org